Exploring the expression of ORAI2, DYRK2, and GATAD1 genes in osteosarcoma
Description
Osteosarcoma is a rare, aggressive cancer that accounts for less than 1% of all cancers diagnosed annually in the United States. The overall 5-year survival for all patients is 59%. Given the rarity and aggressiveness of osteosarcoma, we aimed to identify potential gene targets by analyzing differential gene expressions between osteosarcoma and normal tissues. Using the R2 Genomics Analysis and Visualization Platform (R2), we selected two human datasets to compare the gene expression of the GATA zinc-finger domain containing-1 (GATAD1), the dual specificity tyrosine-phosphorylation-regulated kinase-2 (DYRK2), and the ORAI calcium release-activated calcium modulator-2 (ORAI2). Each dataset contained osteosarcoma specimens (dataset-1, n=14; dataset-2, n=88) and normal tissues (dataset-1, n=4; dataset-2, n=39). We used the Pearson coefficient of determination (R²) function and Kaplan Meier survival curves to determine if there were correlations between the three genes and the overall patient survival. Results showed the expression of the selected genes was significantly elevated in patients with osteosarcoma compared to normal tissue controls. Using Kaplan Meier survival curves, it was determined that osteosarcoma patients expressing high levels of GATAD1, DYRK2, or ORAI2 had an overall worse survival probability compared to patients who expressed low levels of these genes. ORAI2 gene expression was found to be significantly correlated with DYRK2 and GATAD1 expression, while GATAD1 gene expression was found to be significantly correlated with DYRK2 expression in osteosarcoma tissue. These results may help advance our understanding of osteosarcoma, providing valuable insights to guide future research and clinical strategies aimed at improving patient outcomes.
Citation Information
Deets, Madeline and Ananieva-Stoyanova, Elitsa, "Exploring the expression of ORAI2, DYRK2, and GATAD1 genes in osteosarcoma" (2026). Office of Research DMU Research Symposium. 92.
https://digitalcommons.dmu.edu/researchsymposium/2025rs/2025abstracts/92
Exploring the expression of ORAI2, DYRK2, and GATAD1 genes in osteosarcoma
Osteosarcoma is a rare, aggressive cancer that accounts for less than 1% of all cancers diagnosed annually in the United States. The overall 5-year survival for all patients is 59%. Given the rarity and aggressiveness of osteosarcoma, we aimed to identify potential gene targets by analyzing differential gene expressions between osteosarcoma and normal tissues. Using the R2 Genomics Analysis and Visualization Platform (R2), we selected two human datasets to compare the gene expression of the GATA zinc-finger domain containing-1 (GATAD1), the dual specificity tyrosine-phosphorylation-regulated kinase-2 (DYRK2), and the ORAI calcium release-activated calcium modulator-2 (ORAI2). Each dataset contained osteosarcoma specimens (dataset-1, n=14; dataset-2, n=88) and normal tissues (dataset-1, n=4; dataset-2, n=39). We used the Pearson coefficient of determination (R²) function and Kaplan Meier survival curves to determine if there were correlations between the three genes and the overall patient survival. Results showed the expression of the selected genes was significantly elevated in patients with osteosarcoma compared to normal tissue controls. Using Kaplan Meier survival curves, it was determined that osteosarcoma patients expressing high levels of GATAD1, DYRK2, or ORAI2 had an overall worse survival probability compared to patients who expressed low levels of these genes. ORAI2 gene expression was found to be significantly correlated with DYRK2 and GATAD1 expression, while GATAD1 gene expression was found to be significantly correlated with DYRK2 expression in osteosarcoma tissue. These results may help advance our understanding of osteosarcoma, providing valuable insights to guide future research and clinical strategies aimed at improving patient outcomes.
